Despite its advertisement as a [[recreational drug|recreational substance]], mCPP is actually generally considered to be an unpleasant experience and is not desired by drug users.<ref name="pmid19304863"/> It lacks any [[reinforcing]] or [[hallucinogen]]ic effects,<ref name="pmid14563541">{{cite journal |vauthors=Tancer M, Johanson CE | title = Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP | journal = Drug and Alcohol Dependence | volume = 72 | issue = 1 | pages = 33–44 |date=October 2003 | pmid = 14563541 | doi = 10.1016/S0376-8716(03)00172-8| url = http://linkinghub.elsevier.com/retrieve/pii/S0376871603001728}}</ref><ref name="pmid9933142" /> produces [[dysphoric]], [[depression (mood)|depressive]], and [[anxiogenic]] effects in rodents and humans,<ref name="pmid19269287">{{cite journal |vauthors=Rajkumar R, Pandey DK, Mahesh R, Radha R | title = 1-(m-Chlorophenyl)piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT(2A) receptors: proposal of a modified rodent antidepressant assay | journal = European Journal of Pharmacology | volume = 608 | issue = 1-3 | pages = 32–41 |date=April 2009 | pmid = 19269287 | doi = 10.1016/j.ejphar.2009.02.041 | url = http://linkinghub.elsevier.com/retrieve/pii/S0014-2999(09)00198-8}}</ref><ref name="pmid2767117">{{cite journal |vauthors=Kennett GA, Whitton P, Shah K, Curzon G | title = Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists | journal = European Journal of Pharmacology | volume = 164 | issue = 3 | pages = 445–54 |date=May 1989 | pmid = 2767117 | doi = 10.1016/0014-2999(89)90252-5| url = }}</ref> and can induce [[panic attack]]s in individuals susceptible to them.<ref name="pmid1756202">{{cite journal |vauthors=Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW | title = Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects | journal = Biological Psychiatry | volume = 30 | issue = 10 | pages = 973–84 |date=November 1991 | pmid = 1756202 | doi = 10.1016/0006-3223(91)90119-7| url = }}</ref><ref name="pmid3110824">{{cite journal |vauthors=Charney DS, Woods SW, Goodman WK, Heninger GR | title = Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects | journal = Psychopharmacology | volume = 92 | issue = 1 | pages = 14–24 | year = 1987 | pmid = 3110824 | doi = 10.1007/bf00215473| url = }}</ref><ref name="pmid17481859">{{cite journal |vauthors=Van Veen JF, Van der Wee NJ, Fiselier J, Van Vliet IM, Westenberg HG | title = Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls | journal = European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology | volume = 17 | issue = 10 | pages = 637–42 |date=October 2007 | pmid = 17481859 | doi = 10.1016/j.euroneuro.2007.03.005 | url = http://linkinghub.elsevier.com/retrieve/pii/S0924-977X(07)00082-X}}</ref><ref name="pmid15336303">{{cite journal |vauthors=van der Wee NJ, Fiselier J, van Megen HJ, Westenberg HG | title = Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine in patients with panic disorder and controls | journal = European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology | volume = 14 | issue = 5 | pages = 413–7 |date=October 2004 | pmid = 15336303 | doi = 10.1016/j.euroneuro.2004.01.001 | url = http://linkinghub.elsevier.com/retrieve/pii/S0924977X0400015X}}</ref> It also worsens [[obsessive-compulsive disorder|obsessive–compulsive]] symptoms in people with the disorder.<ref name="pmid1728249">{{cite journal |vauthors=Hollander E, DeCaria CM, Nitescu A, etal | title = Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers | journal = Archives of General Psychiatry | volume = 49 | issue = 1 | pages = 21–8 |date=January 1992 | pmid = 1728249 | doi = 10.1001/archpsyc.1992.01820010021003| url = http://archpsyc.ama-assn.org/cgi/pmidlookup?view=long&pmid=1728249}}</ref><ref name="pmid9676822">{{cite journal |vauthors=Broocks A, Pigott TA, Hill JL, etal | title = Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results | journal = Psychiatry Research | volume = 79 | issue = 1 | pages = 11–20 |date=June 1998 | pmid = 9676822 | doi = 10.1016/S0165-1781(98)00029-8| url = http://linkinghub.elsevier.com/retrieve/pii/S0165178198000298}}</ref><ref name="pmid2018816">{{cite journal |vauthors=Pigott TA, Zohar J, Hill JL, etal | title = Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder | journal = Biological Psychiatry | volume = 29 | issue = 5 | pages = 418–26 |date=March 1991 | pmid = 2018816 | doi = 10.1016/0006-3223(91)90264-M| url = }}</ref>

 
mCPP is known to induce [[headache]]s in humans and has been used for testing potential [[antimigraine]] medications.<ref name="Leone">{{cite journal | last = Leone | first = M |author2=A Attanasio |author3=D Croci |author4=G Filippini |author5=D D'Amico |author6=L Grazzi |author7=A Nespolo |author8=G Bussone | title = The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: A controlled study | journal = Neurology | volume = 55 | issue = 1 | pages = 136–139 | date = July 12, 2000 | url = | doi = 10.1212/wnl.55.1.136| pmid = 10891925}}</ref><ref name="Martin et al.">Martin RS & Martin GR. Investigations into migraine pathogenesis: time course for effects of m-CPP, BW723C86 or glyceryl trinitrate on appearance of Fos-like immunoreactivity in rat trigeminal nucleus caudalis (TNC). Cephalalgia 2001; 21:46–52. London. {{ISSN|0333-1024}}</ref><ref name="Petkov et al.">Petkov VD, Belcheva S, Konstantinova E. Anxiolytic effects of dotarizine, a possible antimigraine drug. Methods Find Exp Clin Pharmacol. 1995 Dec;17(10):659-68.</ref> It has potent [[anorectic]] effects and has encouraged the development of selective [[5-HT2C receptor|5-HT<sub>2C</sub> receptor]] [[agonist]]s for the treatment of [[obesity]] as well.<ref name="pmid2906446">{{cite journal |vauthors=Kennett GA, Curzon G | title = Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors | journal = Psychopharmacology | volume = 96 | issue = 1 | pages = 93–100 | year = 1988 | pmid = 2906446 | doi = 10.1007/BF02431539| url = }}</ref><ref name="pmid9361339">{{cite journal |vauthors=Sargent PA, Sharpley AL, Williams C, Goodall EM, Cowen PJ | title = 5-HT2C receptor activation decreases appetite and body weight in obese subjects | journal = Psychopharmacology | volume = 133 | issue = 3 | pages = 309–12 |date=October 1997 | pmid = 9361339 | doi = 10.1007/s002130050407| url = http://link.springer.de/link/service/journals/00213/bibs/7133003/71330309.htm}}</ref><ref name="pmid15719229">{{cite journal |vauthors=Hayashi A, Suzuki M, Sasamata M, Miyata K | title = Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats | journal = Psychopharmacology | volume = 178 | issue = 2-3 | pages = 241–9 |date=March 2005 | pmid = 15719229 | doi = 10.1007/s00213-004-2019-z}}</ref><ref name="pmid17209663">{{cite journal |vauthors=Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE | title = Serotonergic drugs : effects on appetite expression and use for the treatment of obesity | journal = Drugs | volume = 67 | issue = 1 | pages = 27–55 | year = 2007 | pmid = 17209663 | doi = 10.2165/00003495-200767010-00004| url = http://content.wkhealth.com/linkback/openurl?issn=0012-6667&volume=67&issue=1&spage=27}}</ref>

 
mCPP possesses significant [[affinity (pharmacology)|affinity]] for the [[5-HT1A receptor|5-HT<sub>1A</sub>]], [[5-HT1B receptor|5-HT<sub>1B</sub>]], [[5-HT1D receptor|5-HT<sub>1D</sub>]], [[5-HT2A receptor|5-HT<sub>2A</sub>]], [[5-HT2B receptor|5-HT<sub>2B</sub>]], [[5-HT2C receptor|5-HT<sub>2C</sub>]], [[5-HT3 receptor|5-HT<sub>3</sub>]], and [[5-HT7 receptor|5-HT<sub>7</sub> receptor]]s, as well as the [[serotonin transporter|SERT]].<ref name="PDSP" /> It also has some affinity for [[alpha-1 adrenergic|α<sub>1</sub>-adrenergic]], [[alpha-2 adrenergic|α<sub>2</sub>-adrenergic]], [[H1 receptor|H<sub>1</sub>]], [[Imidazoline receptor|I<sub>1</sub>]], and [[norepinephrine transporter|NET]].<ref name="PDSP" /><ref name="pmid7814826">{{cite journal |vauthors=Silverstone PH, Rue JE, Franklin M, etal | title = The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers | journal = International Clinical Psychopharmacology | volume = 9 | issue = 3 | pages = 173–8 |date=September 1994 | pmid = 7814826 | doi = 10.1097/00004850-199409000-00005| url = }}</ref> It behaves as an [[agonist]] at most serotonin receptors.<ref name="pmid503247">{{cite journal |vauthors=Samanin R, Mennini T, Ferraris A, Bendotti C, Borsini F, Garattini S | title = Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats | journal = Naunyn-Schmiedeberg's Archives of Pharmacology | volume = 308 | issue = 2 | pages = 159–63 |date=August 1979 | pmid = 503247 | doi = 10.1007/BF00499059| url = }}</ref><ref name="pmid15888508">{{cite journal |vauthors=Odagaki Y, Toyoshima R, Yamauchi T | title = Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding | journal = Journal of Psychopharmacology (Oxford, England) | volume = 19 | issue = 3 | pages = 235–41 |date=May 2005 | pmid = 15888508 | doi = 10.1177/0269881105051526 | url = http://jop.sagepub.com/cgi/pmidlookup?view=long&pmid=15888508}}</ref> mCPP has been shown to act not only as a [[serotonin reuptake inhibitor]] but as a [[serotonin releasing agent]] as well.<ref name="pmid6610423">{{cite journal |vauthors=Pettibone DJ, Williams M | title = Serotonin-releasing effects of substituted piperazines in vitro | journal = [[Biochemical Pharmacology (journal)|Biochemical Pharmacology]] | volume = 33 | issue = 9 | pages = 1531–5 |date=May 1984 | pmid = 6610423 | doi = 10.1016/0006-2952(84)90424-6| url = http://linkinghub.elsevier.com/retrieve/pii/0006-2952(84)90424-6}}</ref>

 
mCPP's strongest actions are at the 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors and its discriminative cue is mediated primarily by 5-HT<sub>2C</sub>.<ref name="PDSP"/><ref name="pmid8082704">{{cite journal |vauthors=Callahan PM, Cunningham KA | title = Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP) | journal = European Journal of Pharmacology | volume = 257 | issue = 1-2 | pages = 27–38 |date=May 1994 | pmid = 8082704 | doi = 10.1016/0014-2999(94)90690-4| url = http://linkinghub.elsevier.com/retrieve/pii/0014-2999(94)90690-4}}</ref><ref name="pmid9683007">{{cite journal |vauthors=Gommans J, Hijzen TH, Maes RA, Olivier B | title = Discriminative stimulus properties of mCPP: evidence for a 5-HT2C receptor mode of action | journal = Psychopharmacology | volume = 137 | issue = 3 | pages = 292–302 |date=June 1998 | pmid = 9683007 | doi = 10.1007/s002130050622| url = http://link.springer.de/link/service/journals/00213/bibs/8137003/81370292.htm}}</ref> Its negative effects such as [[anxiety]], [[headache]]s, and [[anorexia (symptom)|appetite loss]] are likely mediated by its actions on the 5-HT<sub>2C</sub> receptor.<ref name="pmid2767117"/><ref name="pmid2906446"/><ref name="pmid3401632">{{cite journal |vauthors=Kennett GA, Curzon G | title = Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors | journal = [[British Journal of Pharmacology]] | volume = 94 | issue = 1 | pages = 137–47 |date=May 1988 | pmid = 3401632 | pmc = 1853919 | doi = 10.1111/j.1476-5381.1988.tb11508.x| url = }}</ref> Other effects of mCPP include [[nausea]], [[hypoactivity]], and [[penile erection]], the latter two the result of increased 5-HT<sub>2C</sub> activity and the former likely via 5-HT<sub>3</sub> stimulation.<ref name="pmid2775468">{{cite journal |vauthors=Kłodzińska A, Jaros T, Chojnacka-Wójcik E, Maj J | title = Exploratory hypoactivity induced by m-trifluoromethylphenylpiperazine (TFMPP) and m-chlorophenylpiperazine (m-CPP) | journal = Journal of Neural Transmission. Parkinson's Disease and Dementia Section | volume = 1 | issue = 3 | pages = 207–18 | year = 1989 | pmid = 2775468 | doi = 10.1007/BF02248670| url = }}</ref><ref name="pmid7862925">{{cite journal |vauthors=Walsh AE, Smith KA, Oldman AD, Williams C, Goodall EM, Cowen PJ | title = m-Chlorophenylpiperazine decreases food intake in a test meal | journal = Psychopharmacology | volume = 116 | issue = 1 | pages = 120–2 |date=September 1994 | pmid = 7862925 | doi = 10.1007/BF02244883| url = }}</ref><ref name="pmid8001637">{{cite journal |vauthors=Stancampiano R, Melis MR, Argiolas A | title = Penile erection and yawning induced by 5-HT1C receptor agonists in male rats: relationship with dopaminergic and oxytocinergic transmission | journal = European Journal of Pharmacology | volume = 261 | issue = 1-2 | pages = 149–55 |date=August 1994 | pmid = 8001637 | doi = 10.1016/0014-2999(94)90313-1| url = http://linkinghub.elsevier.com/retrieve/pii/0014-2999(94)90313-1}}</ref>

 
In comparison studies, mCPP has approximately 10-fold [[binding selectivity|selectivity]] for the human 5-HT<sub>2C</sub> receptor over the human 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors (K<sub>i</sub> = 3.4&nbsp;nM vs. 32.1 and 28.8&nbsp;nM).<ref name="pmid9933142">{{cite journal | vauthors = Nelson DL, Lucaites VL, Wainscott DB, Glennon RA | title = Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors | journal = Naunyn Schmiedebergs Arch. Pharmacol. | volume = 359 | issue = 1 | pages = 1–6 | year = 1999 | pmid = 9933142 | doi = | url = }}</ref> It acts as a [[partial agonist]] of the human 5-HT<sub>2C</sub> receptor but as an [[receptor antagonist|antagonist]] of the human 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors.<ref name="pmid9933142" /><ref name="pmid8856697">{{cite journal | vauthors = Thomas DR, Gager TL, Holland V, Brown AM, Wood MD | title = m-Chlorophenylpiperazine (mCPP) is an antagonist at the cloned human 5-HT2B receptor | journal = Neuroreport | volume = 7 | issue = 9 | pages = 1457–60 | year = 1996 | pmid = 8856697 | doi = | url = }}</ref> In accordance with its lack of agonism towards the human 5-HT<sub>2A</sub> receptor, there are no reports that mCPP produces [[hallucinogen]]ic effects in humans.<ref name="pmid9933142" />

 
mCPP is a metabolite of a variety of other piperazine drugs including [[trazodone]], [[nefazodone]], [[etoperidone]], [[enpiprazole]], [[mepiprazole]], [[cloperidone]], and [[peraclopone]].<ref name="pmid21744514">{{cite journal | vauthors = Elliott S | title = Current awareness of piperazines: pharmacology and toxicology | journal = Drug Test Anal | volume = 3 | issue = 7-8 | pages = 430–8 | year = 2011 | pmid = 21744514 | doi = 10.1002/dta.307 | url = }}</ref>{{Additional citation needed|date=September 2017}} It is formed by [[dealkylation]] via [[CYP3A4]].<ref name="pmid21744514" /> mCPP may be responsible for some of their side effects.{{Citation needed|date=September 2017}}
